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Progress Toward
Doing the Right Thing*
James C. Blankenship, MD
Danville, Pennsylvania
Two thousand years ago, the writer of James neatly sum-
marized 2 of the knottiest problems in interventional
cardiology: “To him who knows to do good and does not do it,
to him it is [wrong]” (James 4:17). These 2 problems are:
) identifying the “right thing to do”; and 2) getting it done.
n this issue of JACC: Cardiovascular Interventions, Marso et
l. (1) try to take us closer to “finding the right thing to do.”
In the past 2 years, 2 documents from the American
eart Association, American College of Cardiology Foun-
ation, and the Society for Cardiovascular Angiography and
nterventions have attempted to identify the “right thing to
o” (2). The 2009 Appropriate Use Criteria (AUC) (3) and
the 2011 Percutaneous Coronary Intervention (PCI)
Guidelines (4) used evidence and expert opinion to guide
use of PCI in a wide variety of scenarios.
See page 229
The authors of these documents recognized them to be
imperfect, not fully evidence-based, and rapidly outdated by
new developments. These criticisms are being addressed.
For example, the percentage of recommendations based on
published evidence (Level of Evidence: A or B) increased
from 51% in the 2005 PCI guidelines (5) to 66% in the 2011
PCI guidelines. An updated version of the 2009 PCI AUC
is expected in early 2012, and plans are already underway to
update the 2011 PCI guidelines.
Constructive criticism helps physicians put guidelines and
AUC in perspective and improve their next iterations. As
such, the critique by Marso et al. (1) of the AUC is helpful.
Some of their most compelling criticisms are:
1. The 17-person technical panel that developed appro-
priateness scores included only 4 interventional cardi-
ologists, so that collectively, the group may have failed
to recognize some benefits of PCI.
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contents of this paper to disclose.2. 85 cardiologists evaluating the AUC rankings dis-
agreed substantially with the AUC technical panel
scores, casting further doubt on the validity of some
AUC ratings as “appropriate,” “uncertain,” and “inap-
propriate” (6).
3. Criteria for rating stress test results as “high,” “inter-
mediate,” or “low” risk were vague, and assignment to
these categories may have been unreliable.
4. The AUC rates PCI for class II angina with low-risk
stress test results and less than maximal antianginal
therapy as “inappropriate,” ignoring the fact that for
many patients, class II angina severely limits quality of
life (7,8).
5. National Cardiovascular Data Registry ratings of ap-
propriateness provided to hospitals every quarter are
based on data that are self-reported, unaudited, and
potentially biased.
In a larger sense, the AUC and PCI guidelines attempt
to codify and clarify what is “the right thing to do.” They
represent the best efforts of intelligent, well-meaning
professionals to identify what we know, but as with all
such efforts, these are doomed to imperfection. There will
always be inadequate evidence, disagreement among ex-
perts, and new research rendering current knowledge
obsolete.
The next iterations of the guidelines and AUC will be
improved but will never fully define the best treatment
decision for a particular patient. This is because: 1) occa-
sionally, patients will have exceptional circumstances that
dictate treatment different from that recommended by AUC
and guidelines; and 2) different patients experience a given
level of symptoms differently. In 1 study, 33% of patients
were “more bothered” by class II angina than the average
patient with class III/IV angina, and patients that are
“more bothered” by their symptoms will take greater risks
to relieve them than patients “less bothered” (8). Deter-
minations of appropriateness by the AUC based on
angina class fail to take patients’ perceptions and prefer-
ences into account. This is a fundamental flaw, because
patients’ perceptions and preferences are a critical com-
ponent of decision making (7,9).
Factoring in patient preferences raises a host of new prob-
lems. Patients’ preferences are routinely based on incorrect
perceptions and nonobjective factors (Table 1 [10–18]). Pa-
tients routinely overestimate the benefits of PCI, underesti-
mate its risks, and underestimate the efficacy of medical
therapy (10–14,17,18). Patients tend to discount the some-
times superior benefits of 1 treatment (e.g., CABG for very
complex triple vessel disease) because those benefits accrue
later, and instead prefer the more immediate but lesser benefits
of another treatment (e.g., PCI) because they accrue sooner
(temporal discounting) (15). Patients’ preference for conve-
nience often leads to the same result: PCI provides faster
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 2 , 2 0 1 2 Blankenship
F E B R U A R Y 2 0 1 2 : 2 3 6 – 8 Editorial Comment
237relief than optimal medical therapy, especially when done
at the same session as diagnostic catheterization. Physi-
cians need to minimize these biases by providing accurate
information and encouraging rational decision making,
which may require delaying PCI (19), employing the
“heart team approach” (4), or perhaps employing inno-
vative methods of providing informed consent (20).
The final aspect of “doing the right thing” resides with
physicians. Physicians are at risk for making nonevidence-
based treatment decisions favoring PCI due to lack of
awareness of recent research, guidelines, or AUC, malprac-
tice concerns, and the “chagrin factor,” which reflects their
fear of adverse consequences resulting from treatment de-
cisions (10,18). Physicians should keep up to date with
recent data, be aware of standards such as the AUC and PCI
guidelines, seek to understand patients’ preferences, and
help them make rational decisions.
In summary, the physician and patient seeking to do “the
right thing” face many pitfalls. The patient is responsible for
carefully considering information provided by caregivers,
identifying personal preferences, and then acting as a
therapeutic partner as treatment is delivered. The physician
is responsible for knowing current data and standards
regarding treatment options, providing the patient with
information that allows for truly informed consent, under-
standing the patient’s preferences, providing patient-specific
advice, and then helping the patient obtain appropriate
Table 1. Nonevidence-Based Factors That May Inappropriately Influence
Treatment Decisions in Patients With Stable Ischemic Heart Disease
Patient factors
Patients often overestimate the likelihood that percutaneous coronary
intervention (PCI) will prevent myocardial infarction and/or death (10–14)
Patients often underestimate the risks of PCI (11,13)
Patients overestimate the beneﬁts of PCI  OMT compared with OMT alone
(10,14)
Patients underestimate the efﬁcacy of OMT (10)
Patients value convenience and may give it undue weight in
treatment decisions
Patients value immediate beneﬁts more than later beneﬁts (temporal
discounting) (15)
Physician factors
Physicians may overestimate the beneﬁt of PCI and underestimate its risks
(10,16)
Physicians may recommend PCI in the absence of an evidence base for
this recommendation (10,13)
Physicians may perceive action (i.e., PCI  OMT) as preferable to inaction
(i.e., OMT) (16–18)
Physicians may perceive malpractice risk as lower with action
(i.e., PCI  OMT) versus inaction (i.e., OMT) (16,17)
Cardiologists may perceive that primary care physicians referring patients
prefer PCI  OMT over OMT (16,17)
OMT optimal medical therapy; PCI percutaneous coronary intervention.medical care. It is particularly important when differenttreatment options are likely to produce similar outcomes,
that the physician respect patients’ autonomy and en-
courage them to choose a strategy most consistent with their
preferences.
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